Inhibitory effects of eplerenone on the mRNA and protein expression of Kv1.3 and other channels of CD4+T lymphocyte in patients with chronic heart failure

Abstract

Abstract:

AIM: To investigate the reversing effect of eplerenone on chronic heart failure through regulating the Kv1.3 channel of CD4+ T lymphocytes. METHODS: Thirty cases of chronic heart failure as CHF group and twenty cases of normal people as control group were collected from the First Affiliated Hospital of Xinjiang Medical University. CD4+ T lymphocyte was sorted by using immune magnetic bead which separated from peripheral blood, and its purity was tested by flow cytometry. The minimum effective concentration of EPL incubation CD4+ T lymphocyte proliferation was found by the CCK-8 technic; Control group, CHF group and CHF + EPL group were established. The expression of channel gene, Kv1.3, KCa3.1 and CRAC on the CD4+ T cell membrane were detected with RT-qPCR technique. And the protein expression of Kv1.3 channels on CD4+ T cell was detected by Western blot. RESULTS: 30 μmol/L was detedted as the prefect concentration for EPL. Compared with control group, the expression of mRNA and protein for Kv1.3 channel in CHF group were increased 10.74 times and 1.20 times, respectively (P<0.01), while that in the EPL+CHF group was decreased by 64.80% and 39.62%, respectively (P<0.01); the mRNA expressions of KCa3.1 and CRAC channel were also increased 4.73 times and 3.77 times, respectively in CHF group (P<0.01) but it decreased after exposed to EPL (decreased by 19.30% and 37.14%，P<0.01). CONCLUSION: Eplerenone can down-regulate the expression of Kv1.3, KCa3.1 and CRAC channel, especial the Kv1.3, which in accordance with higher expression of the three channels protein on the CD4+ T cell separated from CHF patients. And the aldosterone antagonist may inhibit the actibation of Kv1.3 membrane channel on the CD4+ T cell, which is beneficial for the CHF.

Key words: chronic heart failure, CD4+ T lymphocytes, eplerenone, Kv1.3 channel, inhibition

CLC Number:

R541

LI Shaohua, YILI Hamujiang·KE Youmu, XU QI, SHAO Peipei, CHENG Lufeng. Inhibitory effects of eplerenone on the mRNA and protein expression of Kv1.3 and other channels of CD4+T lymphocyte in patients with chronic heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1259-1264.

References

［1］Chang YY, Chen A, Wu XM, et al. Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure［J］. Int J Med Sci, 2014, 13, 11(11): 1098-106.
［2］Kasal DA, Schiffrin EL. Angiotensin ii, aldosterone, and anti-inflammatory lymphocytes: Interplay and therapeutic opportunities ［J］. Int J Hypertens, 2012, 21: 829-786.
［3］别发瀛. 老年慢性心力衰竭患者联合治疗中出现严重高钾血症3例分析［J］. 临床急诊杂志, 2014, 11(2): 115-116.
［4］Michea L,Delpiano AM,Hitschfeld C,et al.Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels［J］. Endocrinology,146(3):973-980.
［5］Ferrario CM, Schiffrin EL. Role of mineralocorticoid receptor antagonists in cardiovascular disease ［J］. Circ Res, 2015, 116(1): 206-213.
［6］Chiang EY,Li T,Jeet S,et al.Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions［J］. Nature Communications,2017,8: 14644.
［7］Panyi G. Biophysical and pharmacological aspects of K+ channels in T lymphocytes［J］. Eur Biophys J, 2005, 34(6): 515-529.
［8］Lam J, Wulff H. The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression［J］. Drug Dev Res, 2011, 72(7): 573-584.
［9］Gocke AR, Lebson LA, Grishkan IV, et al. Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis［J］. J Immunol, 2012, 15, 188(12): 5877-5886.
［10］张邱兵, 张源明, 程路峰. 替米沙坦对新疆哈萨克族高血压患者外周血T淋巴细胞活化增殖后IKCa1钾通道电流的阻滞作用［J］. 中华医学杂志, 2014, 94(3): 182-186.
［11］Varga Z, Csepany T, Papp F, et al. Potassium channel expression in human CD4+ regulatory and naive T cells from healthy subjects and multiple sclerosis patients［J］. Immunol Lett, 2009, 124(2): 95-101.
［12］Di L, Srivastava S, Zhdanova O, et al. Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis［J］. Proc Natl Acad Sci U S A, 2010, 107(4): 1541-1546.
［13］Hansen LK. The role of T cell potassium channels, KV1.3 and KCa3.1, in the inflammatory cascade in ulcerative colitis［J］. Dan Med J, 2014, 61(11): B4946.
［14］Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes［J］. Immunol Rev, 2009, 231(1): 59-87.

[1]	CHENG Kuan. New progress in research and application of fenneridone [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 450-456.
[2]	XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
[3]	PENG Jing, LIU Jun, XU Huifang, LI Yueran, JIANG Jia, WANG Sheng, ZHOU Dexi, ZHU Yanhong, YANG Kui, LUAN Jiajie. Correlation study between cytochrome P4502C19 gene polymorphism or metabolic type and ADP induced-platelet aggregation inhibition and clopidogrel resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 746-751.
[4]	FAN Jianfeng，FANG Yi，ZHENG Chunhua. Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814.
[5]	ZHANG Jingxian, CHEN Tao, ZHANG Xiangqi, SHI Meizhi, CHEN Junjun, ZHANG Kezhi, YANG Jiao, GUO Cheng, WANG Laiyou, HAN Yonglong. Inhibition effects of Danhong injection on three transporters in human primary hepatocytes in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 389-394.
[6]	CAI Jiaqin, WEI Xiaoxia, HUANG Xuhui, ZHUANG Jie, SUN Hong. Oxymatrine inhibits invasion and metastasis of triple-negative breast cancer cells by regulating epithelial mesenchymal transition [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 13-17.
[7]	ZHANG Peiyu, REN Jing, ZHI Wenqian, LIU Chengming, GAO Na. Inhibition of CYP450 activity by honokiol and other four components of Chinese traditionalmedicine in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 922-926.
[8]	CHEN Yongcai, ZHOU Bin, CHEN Xuemin, WENG Jinyue. Effect of curcumin on the human colon cancer cells SW480 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 526-530.
[9]	WU Changjuan, TANG Tiansheng. Efficacy of Zhenyuan capsule as adjuvant therapy for chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 299-304.
[10]	ZHONG Liangrui, CHEN Hua, JING Jing, QIAO Hongli, WEI Kemin, WANG Weidong. Radix tetrastigma hemsleyani flavone suppresses human lung carcinoma A549 cell via proteasome inhibition [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1123-1126.
[11]	YANG Liu, GUO Yi. Updating the evidence for the effect trimetazidine and shexiang baoxin pills on chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 644-650.
[12]	LIU Li-ya, HAN Yong-long, YU Qi, ZHU Jin-hui, GUO Cheng. In vitro inhibition of 4 anti-tumor traditional Chinese medicine injections on activities of 7 main cytochrome P450s in human liver microsome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 522-527.
[13]	ZHANG Ran-ran, YANG Guo-ping, JING Ning-ning, HUANG Jie, HUANG Lu, WANG Yan. Effects of food on Cytochrome P450 drug metabolic enzymes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 200-205.
[14]	JIA Yuan-wei, PENG Ying, SUN Jian-guo, XIE Hai-tang, CHU Ji-ru, SHEN Jie. “N-in-One Cocktail” method to evaluate inhibition effects of 4-hydroxylmethylphenyl-O-β-D-pyranosyl alloside on CYP450 enzymes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1371-1375.
[15]	LIU Hai-yan, ZHANG Le-duo, XIANG Zhi-xiong, MIAO Hong. Inhibition study of cytochrome P450 isozymes by (5R)-5-hydroxytriptolide using in vitro “cocktail” method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1211-1218.